Disease Markers / 2019 / Article / Tab 3

Research Article

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 3

Association of MMP9 SNPs with serum MMP9 levels before treatment.

Genotype (%)Serum MMP9 (ng/ml)
Median (27%-75%)

rs17576 c.836A>G, p.Gln279Arg0.041a
AA45 (41.7) [2]669.8 (429.4-973.2)Reference
AG55 (50.9)698.5 (530.2-1244.5)0.139
GG8 (7.4)1313.6 (689.4-1591.6)0.013
AG+GG63 (58.3)869.6 (546.1-1420.2)0.053
rs2250889 c.1721C>G, p.Arg574Pro
CC99 (91.7) [2]753.8 (530.2-1219.1)Reference
CG9 (8.3)503.0 (430.0-1084.7)0.232
rs17577 c.2003G>A, p.Arg668Gln0.146a
GG76 (69.7) [1]661.8 (435.9-1130.8)Reference
GA30 (27.5)1035.5 (538.6-1411.7)0.187
AA2 (2.8)1207.2 (820.4-1207.2)0.120
GA+AA32 (30.3)1053.5 (545.1-1414.5)0.100
rs20544 c.3C>T0.222a
CC18 (16.7) [2]981.0 (558.0-1441.2)Reference
CT54 (50.0)721.5 (493.9-1225.5)0.275
TT36 (33.3)687.7 (425.2-975.3)0.093
CT+TT90 (83.3)702.1 (486.8-1176.1)0.148

aCalculated using the Kruskal-Wallis test comparing all three genotypes. Numbers in [] denote missing genotype data.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.